Caroline Dupont - Biomea Fusion Senior Contracts
| BMEA Stock | USD 7.24 0.22 3.13% |
Executive
Caroline Dupont is Senior Contracts of Biomea Fusion
| Address | 900 Middlefield Road, Redwood City, CA, United States, 94063 |
| Phone | 650 980 9099 |
| Web | https://biomeafusion.com |
Biomea Fusion Management Efficiency
The company has return on total asset (ROA) of (0.5638) % which means that it has lost $0.5638 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0451) %, meaning that it created substantial loss on money invested by shareholders. Biomea Fusion's management efficiency ratios could be used to measure how well Biomea Fusion manages its routine affairs as well as how well it operates its assets and liabilities. As of December 1, 2024, Return On Tangible Assets is expected to decline to -0.62. The current year's Return On Capital Employed is expected to grow to -0.68. At present, Biomea Fusion's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 3 M, whereas Total Assets are forecasted to decline to about 127.1 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Caroline MD | Ikena Oncology | 52 | |
| Rose Weldon | Cullinan Oncology LLC | N/A | |
| Elizabeth Gordon | Design Therapeutics | N/A | |
| Mustapha Parekh | Design Therapeutics | N/A | |
| William Winston | Werewolf Therapeutics | N/A | |
| Valdas Jurkauskas | Ikena Oncology | N/A | |
| Kevin Johnston | Cullinan Oncology LLC | N/A | |
| John Moore | Edgewise Therapeutics | 60 | |
| MD FACC | Design Therapeutics | 55 | |
| David MS | Ikena Oncology | N/A | |
| Bob Lally | Ikena Oncology | N/A | |
| Samantha Vuksanic | Ikena Oncology | N/A | |
| Mary Fenton | Cullinan Oncology LLC | 60 | |
| Rebecca Cohen | Ikena Oncology | N/A | |
| Alexander Constan | Ikena Oncology | N/A | |
| Marc MD | Edgewise Therapeutics | 67 | |
| John JD | Edgewise Therapeutics | 60 | |
| Mary CPA | Cullinan Oncology LLC | 60 | |
Management Performance
| Return On Equity | -1.05 | ||||
| Return On Asset | -0.56 |
Biomea Fusion Leadership Team
Elected by the shareholders, the Biomea Fusion's board of directors comprises two types of representatives: Biomea Fusion inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biomea. The board's role is to monitor Biomea Fusion's management team and ensure that shareholders' interests are well served. Biomea Fusion's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biomea Fusion's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Franco CPA, CFO Officer | ||
| Juan MD, Chief Officer | ||
| Caroline Dupont, Senior Contracts | ||
| Naomi Cretcher, Chief Officer | ||
| Heow Tan, Chief Officer | ||
| Stephan MD, Chief Officer | ||
| Franco Valle, CFO Officer | ||
| Ravi Upasani, Executive Property | ||
| Ramses Erdtmann, President, CoFounder | ||
| Thomas Butler, Chairman CoFounder | ||
| Thorsten Kirschberg, Executive Chemistry |
Biomea Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biomea Fusion a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.05 | ||||
| Return On Asset | -0.56 | ||||
| Current Valuation | 183.98 M | ||||
| Shares Outstanding | 36.24 M | ||||
| Shares Owned By Insiders | 25.01 % | ||||
| Shares Owned By Institutions | 64.50 % | ||||
| Number Of Shares Shorted | 9.41 M | ||||
| Price To Book | 3.45 X | ||||
| EBITDA | (124.62 M) | ||||
| Net Income | (117.25 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Biomea Fusion offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomea Fusion's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomea Fusion Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomea Fusion Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomea Fusion. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For information on how to trade Biomea Stock refer to our How to Trade Biomea Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomea Fusion. If investors know Biomea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomea Fusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.01) | Return On Assets (0.56) | Return On Equity (1.05) |
The market value of Biomea Fusion is measured differently than its book value, which is the value of Biomea that is recorded on the company's balance sheet. Investors also form their own opinion of Biomea Fusion's value that differs from its market value or its book value, called intrinsic value, which is Biomea Fusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomea Fusion's market value can be influenced by many factors that don't directly affect Biomea Fusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomea Fusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomea Fusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomea Fusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.